Spine and Peripheral Nerve Surgery Clinical Trials
North American Clinical Trials Network (NACTN)
The Department of Neurosurgery is a member of the North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury, whose mission is to bring promising therapies out of the laboratory and into clinical trials. A recent Phase I trial showed that the oral medication Riluzole may have some efficacy in reducing impairment if given during the first two weeks after spinal cord injury. A Phase II trial is now being planned to examine the safety and efficacy of Riluzole in more detail.
PI: Graham Creasey NCT00178724
The Canadian Multicentre CSF Monitoring and Biomarker Study (CAMPER)
The Department of Neurosurgery will this year become the first US site in this multi-center study supported by the Rick Hansen Institute of Canada to monitor pressure around the spinal cord during the first week after spinal cord injury and to sample cerebrospinal fluid for biomarkers of injury.
PI: Graham Creasey NCT01279811
Evaluation of Pudendal Nerve Block and Stimulation for Voiding and Continence
This Phase I four-year clinical trial supported by the Department of Defense will evaluate a second generation neural prosthesis for restoring bladder emptying and continence using electrical stimulation without posterior rhizotomy.
PI: Graham Creasey
M6®-C Artificial Cervical Disc IDE Pivotal Study
This two year, multi-center clinical trial is looking at the safety and effectiveness of the Spinal Kinetics M6-C artificial cervical disc in patients with symptomatic cervical radiculopathy, requiring surgical intervention at one vertebral level from C3 to C7. The M6-C artificial cervical disc is an advanced generation artificial disc designed to replicate the anatomic, physiologic and biomechanical characteristics of the native disc.
PI: Lawrence Shuer NCT01609374
A Feasibility Study to Evaluate the Safety and Initial Effectiveness of MR Guided High Intensity Focused Ultrasound (MRgHIFU) in the Treatment of Facetogenic Lumbar Back Pain
The primary purpose of this protocol is to assess the ExAblate 2100 MR guided high intensity focused ultrasound device as an intervention for treatment of facetogenic lower back pain. This is a single group, single arm, open/nonblinded, non-randomized study. The primary outcomes are safety and preliminary efficacy. The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
PI: Pejman Ghanouni NCT02291978
Contact for clinical trials:
Kara Richardson
Co-Manager, Stanford Neuroscience Clinical Research Group
Clinical Research Coordinator
Neurosurgery and Neurology Departments
Stanford School of Medicine
(650) 736-6171